drugset / Trial / NCT05381948
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2023-11-29
- Completion
- 2024-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 0.05 ml | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | CM082 | Unknown | 2060 ug | Intravitreal |
| Subject | CM082 | Unknown | 3090 ug | Intravitreal |